Us intravenous solution market

The U.S intravenous solutions market is estimated to be valued at US$ 3,171.1 Mn in 2023 and is expected to exhibit a CAGR of 7.2% during the forecast period (2023-2030).

Analysts’ Views on U.S Intravenous Solutions Market:

Increasing research and development activities by key players are expected to drive the market over the forecast period. For instance, in June 2022, Intermountain Healthcare, a healthcare company published study data that provided a safer treatment option for IV fluid. According to the study results, patients given lactated Ringer solution as their IV fluid had a 2.2% lower risk of kidney injury and death than when they were given saline.

Figure 1. U.S Intravenous Solutions Market Share (%), By Solution Type, 2023

U.S Intravenous Solutions Market – Drivers

• Increasing launches and regulatory approvals for intravenous solution injection: Market players are involved in launching new intravenous injection solutions, which is expected to boost the growth of the U.S. intravenous solutions market over the forecast period. For instance, in September 2021, Baxter International Inc., a sterile medication production company, announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of premix Norepinephrine Bitartrate in 5% Dextrose Injection (norepinephrine). Norepinephrine is indicated to raise blood pressure in adult patients with severe, acute hypotension (low blood pressure). Baxter’s formulation of norepinephrine is the first and only manufacturer-prepared ready-to-use formulation and is available in 4 mg/250 mL (16 mcg/mL) and 8 mg/250 mL (32 mcg/mL) strengths.
• Increasing prevalence of chronic respiratory diseases: The increasing prevalence of chronic respiratory diseases is expected to increase the demand for intravenous solutions, thereby driving the U.S intravenous solutions market’s growth. For instance, in September 2020, the Centers for Disease Control and Prevention published data according to which 6 in 10 adults in the U.S. have chronc disease, and chronic disease is one of the leading drivers of annual health care costs, which is US$4.1 trillion in 2020. Hence, this is expected to fuel the U.S. intravenous solution market growth over the forecast period.

U.S Intravenous Solutions Market– Impact of Coronavirus (COVID-19) Pandemic

• Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.
• COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, the U.A.E., Egypt, and others, faced problems with the transportation of things from one place to another.
• However, the COVID-19 pandemic had a positive impact on the U.S. intravenous solutions market, owing to the fast spread of coronavirus illness (COVID-19), which will allow patients in intensive care units (ICU) to receive vital nutrients. In addition to this, a significant growth-inducing element is the rise in diabetes, cancer, gastrointestinal problems, and neurological illnesses. Additionally, IV solution therapy's superior efficacy and quicker response time are fostering market expansion. It is employed to treat chronic dehydration, a disease that can lead to weariness, memory loss, irritability, and other health issues. For instance, on May 8, 2023, approximately 60% of the U.S. population grappled with at least one chronic ailment, such as heart disease, stroke, cancer, or diabetes. These chronic conditions not only stand as the primary culprits behind both fatalities and health-related limitations in the United States but also play a significant role in escalating healthcare expenses.

Fig. 2 U.S Intravenous Solutions Market (US$ Mn) & Y-o-Y Growth (%), 2018-2030

U.S Intravenous Solutions Market Segmentation:

The U.S. intravenous solutions market report is segmented by solution type, packaging, application and end user

• By solution type, the market is segmented into saline (normal saline 0.9% NaCl and hypertonic saline), dextran (D5W 5% dextrose in water and analog hypertonic saline), lactated ringer’s, amino acid, vitamins & minerals, heparin and trace elements, and mixed solutions. Out of which, lactated ringer’s is expected to hold a dominant position in the U.S. intravenous solutions market during the forecast period, and this is attributed to the increasing research and development activities by key players and research institutes.
• By packaging, the market is segmented into ampules, vials, cartridges, bottles, and bags (large volume bags-greater than 250ml and small volume bags-less than 250ml). Out of which, bags is expected to dominate the market over the forecast period, and this is attributed to increasing organic strategies such as facility expansion by the key players in the market.
• By application, the market is segmented into basic IV solution, nutritional IV solution, blood IV solution, drug IV solution, irrigation IV solution. Out of which, basic IV solution is expected to dominate the market over the forecast period, and this is attributed to the increasing use of infusion therapy for the treatment of cancer.
• By end user, the market is segmented into hospitals, clinics, ambulatory surgical centers, home care settings, and others. Out of which, hospital is expected to dominate the market over the forecast period, and this is attributed to the increasing use of intravenous solutions in hospitals.

U.S Intravenous Solutions Market: Key Developments

• In June 2022, Breckenridge Pharmaceutical, Inc., a manufacturing company, announced that the U.S. Food and Drug Administration had granted approval of its Abbreviated New Drug Application for cabazitaxel intravenous powder. This product was developed in collaboration with Natco Pharma Limited, a multinational pharmaceutical company. Breckenridge received final approval for the 60mg/1.5mL (40mg/mL) strength.  
• In September 2020, Baxter announced that the U.S. Food and Drug Administration (FDA) had approved Clinimix (amino acids in dextrose) injections and Clinimix E (amino acids with electrolytes in dextrose and calcium) injections, which contain up to 80 g/L of amino acids, the highest protein in any multi-chamber bag available in the U.S.
• In September 2021, ICU Medical, Inc., one of the global leaders in IV therapy, announced that it had acquired Smiths Medical, a company developing and manufacturing various medical products used in infusion therapy, vascular access, and vital care applications. 

U.S Intravenous Solutions Market: Key Trends

• Introduction of systems with advanced technology for IV insertion: The introduction of systems with advanced technology for IV insertion in the market is expected to drive growth of the U.S. intravenous solutions market over the forecast period. For instance, on April 11, 2023, BD (Becton, Dickinson and Company), one of the leading medical technology companies in the U.S. as well as globally, announced the launch of BD Prevue II System, an advanced ultrasound device with a specialized probe designed to provide clinicians with optimal IV placement.

U.S Intravenous Solutions Market: Restraint

• Recall of Intravenous Fluids: The recall of intravenous fluids is expected to hinder market growth over the forecast period. For instance, in March 2022, Fresenius Kabi, one of the global healthcare companies that specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition, issued a voluntary recall of seven lots of sodium acetate intravenous fluid after testing found particulates of carbon and oxygen with traces of sodium, silicon, chromium, aluminum, and cellulose. Voluntary recall of 400 mEq/100 mL (4 mEq/mL) vials sent to hospitals, pharmacies, wholesalers, and distributors across the United States.

Key players are focusing on developing advanced intravenous solutions that are safe and cost-effective, which is expected to drive market growth over the forecast period.

U.S Intravenous Solutions Market - Key Players

Major players operating in the U.S intravenous solutions market include Baxter International Inc., ICU Medical, Inc., Braun Melsungen Ag, and Grifols, S.A.

Definition: Intravenous (IV) fluids are specially formulated liquids that are injected into a vein to prevent or treat dehydration. They are used for people of all ages who are sick, injured, dehydrated from exercise or heat, or undergoing surgery. IV fluids are a simple, safe, and common procedure with a low risk of complications.

U.S Intravenous Solution Market Detailed Segmentation:

• By Solution Type:
  • Saline
    • Normal Saline (0.9% NaCl)
    • Hypertonic Solution
  • Dextran
    • D5W 5% dextrose in water
    • Analog Hypertonic Saline
  • Lactated Ringer’s
  • Amino Acid
  • Vitamins & Minerals
  • Heparin and trace elements
  • Mixed Solutions
• By Packaging:
  • Ampules
  • Vials
  • Cartridges
  • Bottles
  • Bags
    • Large Volume Bags (greater than 250ml)
    • Small Volume Bags (less than 250ml)
• By Application:
  • Basic IV Solution
  • Nutritional IV Solution
  • Blood IV Solution
  • Drug IV Solution
  • Irrigation IV Solution
• By End User:
  • Hospital
  • Clinics
  • Ambulatory Surgical Centers
  • Home Care Settings
  • Others